Hepatic, microsomal, cytochrome P450 monooxygenases provide a crucial protective role in the metabolism and clearance of a wide array of drugs, toxins and endobiotics. The long term objective of this application is to identify structural features that determine the substrate selectivity of individual human P450 enzymes. Active site characteristics affect substrate selectivity, inhibitory potential, the regioselectivity of drug oxidation, as well as the occurrence of drug-drug interactions and activation kinetics. Comparison of recent structures for P450s 1A2, 2A6, 2C8, 2C9 and 3A4 in complex with substrates or inhibitors indicate unique aspects of each active site that contribute to substrate selectivity including the hydration state, the chemical characteristics and positioning of active site residues, as well as the changes imposed on these binding determinants by alterations in active site topology. This underscores the necessity to determine multiple structures of individual enzymes in complex with structurally dissimilar drugs to understand the contribution of conformational flexibility to drug binding. Specific changes in the active site architectures of P450s 1A2, 2D6, 2C19 and 2C9*3 induced by interaction with chemically diverse substrates, inhibitors and activators, alone or in combination, will be identified to delineate the range of adaptive changes that can occur for each enzyme. P450 2A6 is the principal nicotine oxidase in humans. Analysis of the 2A6 active site in complex with different inhibitors indicates several relatively static features that can be productively exploited for the structure based design of more efficacious and selective inhibitors that would have potential benefits as therapeutic aids for smoking cessation. Lead compounds will be assessed for complementarity with the active site, strength of binding, and specificity for 2A6 relative to other P450s. The active site topologies of P450s 1B1, 3A5 and 3A7 will also be determined to identify structural characteristics that control the important functional contribution made by these enzymes to drug metabolism. Collectively, these studies will address significant gaps in our knowledge of P450 structure as it relates to function, and provide important information and tools for prediction of drug metabolism.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
3R01GM031001-28S1
Application #
7922764
Study Section
Xenobiotic and Nutrient Disposition and Action Study Section (XNDA)
Program Officer
Okita, Richard T
Project Start
2009-09-30
Project End
2011-04-30
Budget Start
2009-09-30
Budget End
2011-04-30
Support Year
28
Fiscal Year
2009
Total Cost
$192,897
Indirect Cost
Name
Scripps Research Institute
Department
Type
DUNS #
781613492
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Jennings, Gareth K; Hsu, Mei-Hui; Shock, Lisa S et al. (2018) Noncovalent interactions dominate dynamic heme distortion in cytochrome P450 4B1. J Biol Chem 293:11433-11446
Hsu, Mei-Hui; Savas, Uzen; Johnson, Eric F (2018) The X-Ray Crystal Structure of the Human Mono-Oxygenase Cytochrome P450 3A5-Ritonavir Complex Reveals Active Site Differences between P450s 3A4 and 3A5. Mol Pharmacol 93:14-24
Butler, Christopher R; Ogilvie, Kevin; Martinez-Alsina, Luis et al. (2017) Aminomethyl-Derived Beta Secretase (BACE1) Inhibitors: Engaging Gly230 without an Anilide Functionality. J Med Chem 60:386-402
Hsu, Mei-Hui; Baer, Brian R; Rettie, Allan E et al. (2017) The Crystal Structure of Cytochrome P450 4B1 (CYP4B1) Monooxygenase Complexed with Octane Discloses Several Structural Adaptations for ?-Hydroxylation. J Biol Chem 292:5610-5621
Liu, Renhe; Lyu, Xiaoxuan; Batt, Sarah M et al. (2017) Determinants of the Inhibition of DprE1 and CYP2C9 by Antitubercular Thiophenes. Angew Chem Int Ed Engl 56:13011-13015
Brodney, Michael A; Beck, Elizabeth M; Butler, Christopher R et al. (2015) Utilizing structures of CYP2D6 and BACE1 complexes to reduce risk of drug-drug interactions with a novel series of centrally efficacious BACE1 inhibitors. J Med Chem 58:3223-52
Wang, An; Stout, C David; Zhang, Qinghai et al. (2015) Contributions of ionic interactions and protein dynamics to cytochrome P450 2D6 (CYP2D6) substrate and inhibitor binding. J Biol Chem 290:5092-104
Johnson, Eric F; Connick, J Patrick; Reed, James R et al. (2014) Correlating structure and function of drug-metabolizing enzymes: progress and ongoing challenges. Drug Metab Dispos 42:9-22
Johnson, Eric F; Stout, C David (2013) Structural diversity of eukaryotic membrane cytochrome p450s. J Biol Chem 288:17082-90
Reynald, R Leila; Sansen, Stefaan; Stout, C David et al. (2012) Structural characterization of human cytochrome P450 2C19: active site differences between P450s 2C8, 2C9, and 2C19. J Biol Chem 287:44581-91

Showing the most recent 10 out of 80 publications